Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Xeris Biopharma Holdings Inc (NASDAQ: XERS) closed at $4.58 up 2.69% from its previous closing price of $4.46. In other words, the price has increased by $2.69 from its previous closing price. On the day, 1.82 million shares were traded.
Ratios:
For a deeper understanding of Xeris Biopharma Holdings Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.17 and its Current Ratio is at 1.72.
On March 28, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $5.
On August 28, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $4.50.Craig Hallum initiated its Buy rating on August 28, 2023, with a $4.50 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 09 ’25 when Fairley Ricki Louise bought 56,667 shares for $4.90 per share.
Hecht Beth sold 40,000 shares of XERS for $217,244 on Mar 20 ’25. The insider now owns 1,353,510 shares after completing the transaction at $5.43 per share. On Mar 20 ’25, another insider, Hecht Beth, who serves as the Officer of the company, bought 40,000 shares for $5.14 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.30.
Stock Price History:
Over the past 52 weeks, XERS has reached a high of $6.07, while it has fallen to a 52-week low of $2.03. The 50-Day Moving Average of the stock is -1.48%, while the 200-Day Moving Average is calculated to be 22.96%.
Shares Statistics:
A total of 156.01M shares are outstanding, with a floating share count of 147.60M. Insiders hold about 7.80% of the company’s shares, while institutions hold 54.43% stake in the company.
